Formulation of PPAR-gamma Agonist As Surface Modified PLGA Nanoparticles for Non-invasive Treatment of Diabetic Retinopathy: and Evidences

Overview

Journal Heliyon

Specialty Social Sciences

Date 2020 Aug 25

PMID 32832706

Citations 9

Authors

Umesh D Laddha

Sanjay J Kshirsagar

Affiliations

Soon will be listed here.

Abstract

Diabetic retinopathy is one of the worst complications of diabetes and it is treated by invasive method. We prepared a surface modified poly (D, L-lactide-co-glycolide) i.e. PLGA nanoparticles for delivery of pioglitazone-a peroxisome proliferator-activated receptor-gamma agonist to posterior segment of the eye by topical administration. The present study investigated two grades of PLGA viz. 75:25 and 50:50. Surface modification was performed using polysorbate 80. Nanoparticles were prepared by single emulsion solvent evaporation method and optimized by using 3-factor 3-level Box-Behnken statistical design. Mean particle size, PDI and entrapment efficiency for optimized batch of PLGA 75:25 was found to be 163.23 nm, 0.286 and 91%, whereas; for PLGA 50:50 it was 171.7 nm, 0.280 and 93% respectively. DSC confirms the molecular dispersion of drug in polymer. In vitro release study showed biphasic drug release pattern with 58.48 ± 1.38% and 74.17 ± 1.38% cumulative drug release by PLGA 75:25 and 50:50 nanoparticles at the end of 10h. The release profile of pioglitazone from nanoparticles appeared to fit best with Higuchi model. In vivo study on rat showed dose dependent reduction in vascular endothelial growth factor concentration in vitreous fluid. The study reveals significance of peroxisome proliferator-activated receptor-gamma in management of diabetic retinopathy.

Citing Articles

Natural remedies proposed for the management of diabetic retinopathy (DR): diabetic complications.

Khidr E, Morad N, Hatem S, El-Dessouki A, Mohamed A, El-Shiekh R Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39954069 DOI: 10.1007/s00210-025-03866-w.

A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity.

Eker F, Duman H, Akdasci E, Bolat E, Saritas S, Karav S Molecules. 2024; 29(15).

PMID: 39124888 PMC: 11314082. DOI: 10.3390/molecules29153482.

Recent advances in the treatment and delivery system of diabetic retinopathy.

Wang Z, Zhang N, Lin P, Xing Y, Yang N Front Endocrinol (Lausanne). 2024; 15:1347864.

PMID: 38425757 PMC: 10902204. DOI: 10.3389/fendo.2024.1347864.

Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.

Zhou Y, Xu M, Shen W, Xu Y, Shao A, Xu P Adv Healthc Mater. 2024; 13(17):e2304626.

PMID: 38406994 PMC: 11468720. DOI: 10.1002/adhm.202304626.

Next generation therapeutics for retinal neurodegenerative diseases.

Appell M, Pejavar J, Pasupathy A, Rompicharla S, Abbasi S, Malmberg K J Control Release. 2024; 367:708-736.

PMID: 38295996 PMC: 10960710. DOI: 10.1016/j.jconrel.2024.01.063.

References

Jose S, Juna B, Cinu T, Jyoti H, Aleykutty N . Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies. Colloids Surf B Biointerfaces. 2016; 142:307-314. DOI: 10.1016/j.colsurfb.2016.02.026. View

Alghadyan A . Diabetic retinopathy - An update. Saudi J Ophthalmol. 2013; 25(2):99-111. PMC: 3729572. DOI: 10.1016/j.sjopt.2011.01.009. View

Zhang D, Tan T, Gao L, Zhao W, Wang P . Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm. 2007; 33(5):569-75. DOI: 10.1080/03639040600975147. View

Sah A, Suresh P, Verma V . PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study. Artif Cells Nanomed Biotechnol. 2016; 45(6):1-9. DOI: 10.1080/21691401.2016.1203794. View

Tahara K, Karasawa K, Onodera R, Takeuchi H . Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles. Asian J Pharm Sci. 2020; 12(4):394-399. PMC: 7032217. DOI: 10.1016/j.ajps.2017.03.002. View

Kusari J, Zhou S, Padillo E, Clarke K, Gil D . Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci. 2009; 51(2):1044-51. DOI: 10.1167/iovs.08-3293. View

Lai A, Lo A . Animal models of diabetic retinopathy: summary and comparison. J Diabetes Res. 2013; 2013:106594. PMC: 3826427. DOI: 10.1155/2013/106594. View

Tarr J, Kaul K, Chopra M, Kohner E, Chibber R . Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2014; 2013:343560. PMC: 3914226. DOI: 10.1155/2013/343560. View

Kowluru R, Zhong Q, Santos J, Thandampallayam M, Putt D, Gierhart D . Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr Metab (Lond). 2014; 11(1):8. PMC: 3937140. DOI: 10.1186/1743-7075-11-8. View

10.

Salama A, Mahmoud A, Kamel R . A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations. AAPS PharmSciTech. 2015; 17(5):1159-72. DOI: 10.1208/s12249-015-0448-0. View

11.

Lopez-Gasco P, Iglesias I, Benedi J, Lozano R, Teijon J, Blanco M . Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation. J Microencapsul. 2011; 28(5):417-29. DOI: 10.3109/02652048.2011.576785. View

12.

Kondo M, Niwa T, Okamoto H, Danjo K . Particle characterization of poorly water-soluble drugs using a spray freeze drying technique. Chem Pharm Bull (Tokyo). 2009; 57(7):657-62. DOI: 10.1248/cpb.57.657. View

13.

Kesarla R, Tank T, Vora P, Shah T, Parmar S, Omri A . Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel. Drug Deliv. 2015; 23(7):2363-2370. DOI: 10.3109/10717544.2014.987333. View

14.

Tahara K, Yamamoto H, Kawashima Y . Cellular uptake mechanisms and intracellular distributions of polysorbate 80-modified poly (D,L-lactide-co-glycolide) nanospheres for gene delivery. Eur J Pharm Biopharm. 2010; 75(2):218-24. DOI: 10.1016/j.ejpb.2010.03.013. View

15.

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A . Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018; 10(2). PMC: 6027495. DOI: 10.3390/pharmaceutics10020057. View

16.

Ciudin A, Hernandez C, Simo R . Molecular Implications of the PPARs in the Diabetic Eye. PPAR Res. 2013; 2013:686525. PMC: 3575611. DOI: 10.1155/2013/686525. View

17.

Pandit J, Sultana Y, Aqil M . Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomed Biotechnol. 2016; 45(7):1397-1407. DOI: 10.1080/21691401.2016.1243545. View

18.

Gologorsky D, Thanos A, Vavvas D . Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. Mediators Inflamm. 2012; 2012:629452. PMC: 3457666. DOI: 10.1155/2012/629452. View

19.

Das A, Stroud S, Mehta A, Rangasamy S . New treatments for diabetic retinopathy. Diabetes Obes Metab. 2014; 17(3):219-30. DOI: 10.1111/dom.12384. View

20.

Song M, Roufogalis B, Huang T . Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology. Br J Pharmacol. 2011; 165(1):4-19. PMC: 3252962. DOI: 10.1111/j.1476-5381.2011.01411.x. View